miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2

• Ngā kaituhi matua: Ling Ye (Author), Tao Jiang (Author), Huanzhang Shao (Author), Lin Zhong (Author), Zhaowen Wang (Author), Yuan Liu (Author), Huamei Tang (Author), Bingyu Qin (Author), Xiaoqing Zhang (Author), Junwei Fan (Author)
• Hōputu: Pukapuka
• I whakaputaina: Elsevier, 2017-06-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

5-Fluorouracil (5FU)-based adjuvant therapy is the first-line therapy for treating stage II and III colon cancer after surgery. However, its therapeutic efficacy is limited because of chemoresistance, especially in deficient mismatch repair (dMMR) colon cancer. Here, we first used laser capture micr...